Recent Updates
Recently added Catalysts

Multiple Sclerosis: 6 biotech companies competing in the clinic

Neurology & PsychiatryGold rushData as of 2026-09-04

Competitors6in the clinic
Median market cap$1.3Buniverse median $1.20B
Allocated capital$5.7B$22.5B competing
Phase 3 or filed33 mid, 0 early
Pure plays0this indication only
Capital rank32/299crowding rank 26

Multiple Sclerosis is both crowded and richly priced: 6 companies are in the clinic and the median one is worth $1.3B, against a universe median of $1.20B.

Crowded fields usually trade at a discount per company, so a premium in a field this deep says the market is pricing the size of the prize above the cost of the competition.

3 of the 6 are in Phase 3 or filed, and 6 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$5.7B of allocated capital sits in Multiple Sclerosis, ranking it 32nd of 299 indications by the money committed to it.

Companies developing drugs for Multiple Sclerosis 6

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TGTXTG TherapeuticsUblituximabPhase 36$8.7BNo4 31 Dec 2026
ZBIOZenas BioPharmaOrelabrutinibPhase 33$2.1BNo4 31 Dec 2026
IMUXImmunicIMU-838Phase 32$174MNo2 31 Dec 2026
AXSMAxsome TherapeuticsSolriamfetolPhase 21$10.9BNo4 31 Dec 2026
KYTXKyverna TherapeuticsStandard lymphodepletion regimenPhase 25$516MNo5 31 Dec 2026
TLSATiziana Life SciencesForalumabPhase 21$117MNo3 31 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. AXSM holds 48% of the $22.5B competing in this indication.

Why Multiple Sclerosis is a gold rush

Crowded and richly priced: six or more competitors, and the median one is worth more than the median small or mid cap biotech.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Multiple Sclerosis has 6 competitors and a median of $1.3B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Dravet Syndrome3 companies · $4.2B · median $2.4BConcentrated betTreatment Resistant Depression3 companies · $3.8B · median $1.8BConcentrated betSpinal Muscular Atrophy Type III2 companies · $3.7B · median $4.6BConcentrated betChronic Inflammatory Demyelinating Polyneuropathy2 companies · $3.6B · median $7.0BConcentrated betADHD2 companies · $3.4B · median $6.7BConcentrated betSCN2A Encephalopathy1 company · $3.3B · median $9.9BUncontestedTonic-Clonic Epilepsy1 company · $3.3B · median $9.9BUncontestedFocal Epilepsy6 companies · $8.0B · median $4.2BGold rush

Multiple Sclerosis pipeline questions

Which biotech companies are developing drugs for Multiple Sclerosis?

6 US-listed companies in the $100M to $20B market cap band run clinical programmes in Multiple Sclerosis. The largest and most advanced are TG Therapeutics (TGTX, Ublituximab, Phase 3); Zenas BioPharma (ZBIO, Orelabrutinib, Phase 3); Immunic (IMUX, IMU-838, Phase 3); Axsome Therapeutics (AXSM, Solriamfetol, Phase 2); Kyverna Therapeutics (KYTX, Standard lymphodepletion regimen, Phase 2). The full list of 6 is in the table on this page.

How advanced is the Multiple Sclerosis pipeline?

Of the 6 clinical-stage programmes in Multiple Sclerosis, 3 are in Phase 3 or filed, 3 are in mid-stage development and 0 are in early-stage development.

How much is the typical Multiple Sclerosis biotech company worth?

The median company developing a drug for Multiple Sclerosis is worth $1.3B, against a median of $1.20B across the whole universe. $5.7B of allocated capital sits in the indication, ranking it 32nd of 299.

When is the next Multiple Sclerosis catalyst?

The next dated catalyst in Multiple Sclerosis is TLSA on 31 Oct 2026. 6 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map